Revista fisio&terapia.
June 25, 2026
Daiane Lima de Lara Ziles, Jigliane Tainã Macedo de Souza, Yoda Janaina Ikenohuchi et al.
Psychedelic drugs are emerging as promising alternatives for treating resistant depression, where many patients do not respond to conventional therapies. A systematic review of scientific articles from 2015 to 2025 will analyze clinical studies, randomized controlled trials, and systematic reviews on neurobiological mechanisms, therapeutic outcomes, adverse effects, and ethical aspects. The research aims to consolidate knowledge on efficacy and safety, highlighting clinical advances and limitations, to support mental health professionals and policy makers. It also seeks to destigmatize medicinal psychedelic use and encourage evidence-based practices to improve quality of life for patients with resistant depression.
Revista fisio&terapia.
October 8, 2025
Maurício Pedro Luciano da Costa, Pedro Bruschi Peiretti, Pedro Vinicius Rodrigues Silveira Silva et al.
A resurgence of scientific and clinical interest in psychedelic-assisted therapies, particularly with psilocybin, has been observed. This integrative literature review identifies promising therapeutic effects for treatment-resistant conditions such as depression, anxiety, substance dependence (alcohol and tobacco), and in palliative care for terminally ill patients. The central mechanism of action involves agonism of serotonergic 5-HT2A receptors, inducing altered states of consciousness that, when combined with psychotherapy, foster neural plasticity and promote lasting therapeutic insights. Despite this potential, methodological gaps were identified, including a scarcity of randomized controlled trials and long-term studies, reflecting the recent revival of interest after decades of prohibition. The review concludes that psilocybin has significant therapeutic potential but requires rigorous ethical regulation, professional training, and equitable access policies.
Revista fisio&terapia.
July 14, 2025
Andressa Maria Ferreira Carneiro
Depression affects about 350 million people worldwide, with Brazil having the second highest rate in the Americas at 5.8% of the population. Antidepressants, especially selective serotonin reuptake inhibitors, are the standard treatment, but many patients are turning to unconventional options like Ayahuasca tea. Ayahuasca, a hallucinogenic brew made from Banisteriopsis caapi vine and Psychotria viridis leaves, induces altered consciousness for up to 10 hours. This literature review examines Ayahuasca's therapeutic potential, pharmacological action, history, adverse effects, and contraindications, emphasizing that its use requires caution.
Revista fisio&terapia.
August 15, 2024
Alberto Almeida, Carlos Paulo da Silva, Clara Guerzoni et al.
An integrative review examines the use of psychedelics in psychiatry, covering their historical promise in the 1950s–1970s, subsequent decline due to restrictive policies and stigma, and a recent resurgence driven by new research and changing public perceptions. The review discusses mechanisms of action and neuroplasticity induced by psychedelics, integrative therapeutic approaches, and associated risks and ethical challenges. Compared to traditional treatments that are often ineffective or have significant side effects, psychedelics show potential effectiveness for depression, PTSD, and anxiety. The future appears promising, with research advancements and regulatory changes potentially expanding clinical applications.